Tandem Diabetes Care (TNDM) to Release Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) is expected to be announcing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $277.1440 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Tandem Diabetes Care Trading Up 0.6%

Tandem Diabetes Care stock opened at $19.66 on Thursday. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44. Tandem Diabetes Care has a 1 year low of $9.98 and a 1 year high of $35.12. The firm’s 50-day moving average is $21.10 and its 200-day moving average is $16.84. The company has a market cap of $1.33 billion, a P/E ratio of -6.45 and a beta of 1.68.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TNDM. Caitong International Asset Management Co. Ltd grew its holdings in shares of Tandem Diabetes Care by 200.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company’s stock worth $27,000 after purchasing an additional 1,470 shares in the last quarter. Quarry LP boosted its holdings in shares of Tandem Diabetes Care by 2,597.1% during the third quarter. Quarry LP now owns 3,695 shares of the medical device company’s stock worth $45,000 after purchasing an additional 3,558 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Tandem Diabetes Care by 218.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,168 shares of the medical device company’s stock worth $171,000 after buying an additional 6,290 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Tandem Diabetes Care in the 1st quarter worth approximately $225,000. Finally, Prelude Capital Management LLC bought a new position in shares of Tandem Diabetes Care during the third quarter valued at approximately $228,000.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TNDM. Mizuho raised their price target on Tandem Diabetes Care from $18.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday, December 17th. Citigroup raised their price target on Tandem Diabetes Care from $16.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Tandem Diabetes Care in a report on Wednesday, January 21st. Canaccord Genuity Group set a $35.00 price target on Tandem Diabetes Care and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, Sanford C. Bernstein restated a “market perform” rating and issued a $25.00 target price (up previously from $18.00) on shares of Tandem Diabetes Care in a research note on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $24.35.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.